Answer
Tadomon (tapentadol tartrate) should be avoided during MAO inhibitor treatment and for 14 days afterwards because potential additive effects on synaptic noradrenaline concentrations may cause adverse cardiovascular events, such as hypertensive crisis.
Sources for this answer
- Tadomon 100 mg prolonged-release tabletsG.L Pharma UK Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 4Document updated
Sources checked